PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3228593-0	1988	Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.	Tamoxifen	9-18	serpin family C member 1	Homo sapiens	76-92	
3345487-4	1988	The reduced antithrombin III activity previously described in patients receiving tamoxifen for metastatic breast cancer may reflect disease activity rather than a direct effect of tamoxifen on blood coagulation.	Tamoxifen	81-90	serpin family C member 1	Homo sapiens	12-28	
3607780-0	1987	Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.	Tamoxifen	32-41	serpin family C member 1	Homo sapiens	87-103	
8350363-4	1993	Tamoxifen may also influence risk factors for cardiac and thromboembolic disease (e.g., serum cholesterol and antithrombin III).	Tamoxifen	0-9	serpin family C member 1	Homo sapiens	110-126	
17709798-7	2007	Tamoxifen increased IGFBP-3 and lowered antithrombin-III, C reactive protein, and mammographic density, with greater effects of 5 mg/day.	Tamoxifen	0-9	serpin family C member 1	Homo sapiens	40-56	
12492585-6	2003	Among tamoxifen-treated women, antithrombin and protein S, but not protein C or APC ratio were reduced.	Tamoxifen	6-15	serpin family C member 1	Homo sapiens	31-43	
12492585-7	2003	Sequential antithrombin concentrations with tamoxifen were 114% and 104% (P = 0.001 compared with placebo).	Tamoxifen	44-53	serpin family C member 1	Homo sapiens	11-23	
12492585-10	2003	Reductions of antithrombin and protein S, but not protein C or APC resistance, might relate to the increased risk of venous thrombosis associated with tamoxifen treatment.	Tamoxifen	151-160	serpin family C member 1	Homo sapiens	14-26	
8905024-9	1996	Significant reductions of plasma fibrinogen by 14% and AT III by 8% were seen in women who received tamoxifen.	Tamoxifen	100-109	serpin family C member 1	Homo sapiens	55-61	
6426771-2	1984	In view of this literature, a study of patients on tamoxifen was initiated to determine if a paradoxical estrogenic effect was present as evidenced by lowered levels of antithrombin III (AT III).	Tamoxifen	51-60	serpin family C member 1	Homo sapiens	169-185	
6426771-13	1984	The finding of lowered functional activity of AT III in 42% of tamoxifen-treated patients is preliminary in nature and will require larger confirmatory studies, including further clinical correlation of this observation.	Tamoxifen	63-72	serpin family C member 1	Homo sapiens	46-52	
12783932-10	2003	Several blood biomarkers showed dose-response relationships with tamoxifen, including decreased insulin-like growth factor-I, increased sex hormone-binding globulin, and decreased low-density lipoprotein-cholesterol, ultrasensitive C-reactive protein, fibrinogen, and antithrombin-III levels.	Tamoxifen	65-74	serpin family C member 1	Homo sapiens	268-284	
8790074-8	1996	Naturally occurring anticoagulant proteins such as antithrombin and protein C fell slightly in women treated with tamoxifen.	Tamoxifen	114-123	serpin family C member 1	Homo sapiens	51-63	
8148487-6	1993	We conclude that long-term treatment with tamoxifen for 2 or more years tends to reduce both AT-III and PC, a situation possibly predisposing towards thrombosis.	Tamoxifen	42-51	serpin family C member 1	Homo sapiens	93-99	
1739360-0	1992	Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy.	Tamoxifen	83-92	serpin family C member 1	Homo sapiens	0-16	
1739360-4	1992	Antithrombin III levels, elevated at baseline evaluation, decreased in tamoxifen-treated subjects at 6 months, but no subject exhibited a drop to clinically significant levels.	Tamoxifen	71-80	serpin family C member 1	Homo sapiens	0-16	
35086148-10	2022	Plasma levels of fibrinogen, antithrombin, protein C and TFPI decreased, and free protein S increased in tamoxifen, but not in AI, users.	Tamoxifen	105-114	serpin family C member 1	Homo sapiens	29-41